NFLX vs PFE: Which Is the Better Buy?
Side-by-side comparison of Netflix, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Netflix, Inc. · Communication Services
$76.41
+44.0% upside to fair value
High Conviction
Grade A
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
NFLX has more upside to fair value
(+44.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NFLX |
PFE |
| Current Price |
$76.41 |
$27.64 |
| Fair Value Estimate |
$110.00 |
$30.94 |
| Upside to Fair Value |
+44.0%
|
+12.0%
|
| Market Cap |
$318.2B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
10.6x
|
17.4x
|
| Price / Sales |
6.6x
|
2.5x
|
| Price / FCF |
29.1x
|
14.3x
|
| Revenue Growth YoY |
+13.4%
|
+2.6%
|
| Gross Margin |
49.1%
|
71.3%
|
| Operating Margin |
29.7%
|
25.1%
|
| Return on Equity |
48.0%
|
4.9%
|
| Dividend Yield |
0% |
6.22% |
| FCF Yield |
3.44%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Netflix is a global subscription and advertising-supported entertainment platform with a high-quality brand, content engine, recommendation technology and distribution scale, evidenced by more than 97 billion viewing hours in the first half of 2026 and an audience approaching one billion people. Fundamentals remain strong: revenue grew 13.4% year over year in the most recent quarter, TTM gross, o…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
NFLX |
PFE |
| Zone Low |
$82.50 |
$23.21 |
| Zone High |
$93.50 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|